Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00988494

Enrollment

Registered

2009-10-02

Start date

2009-09-30

Completion date

Unknown

Last updated

2012-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent Corneal Epithelial Defect

Brief summary

Safety and efficacy of DE-105 ophthalmic solution in patients with persistent corneal epithelial defect will be evaluated. Dose-dependent efficacy will be evaluated as well.

Interventions

DRUGDE-105 ophthalmic solution

Topical ocular application

DRUGPlacebo ophthalmic solution

Topical ocular application

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

* Has corneal epithelial defect and decreased corneal sensitivity. * Has undergone continuous treatment for corneal epithelial defect for 1 week or longer.

Exclusion criteria

* Presence of disease such as active ocular infection, or abnormal lid closure. * History or presence of chemical burn, Stevens - Johnson Syndrome, etc. * History of corneal transplantation, LASIK, or hematopoietic stem cell transplantation.

Design outcomes

Primary

Measure	Time frame
Restoration of corneal epithelial defect	Every week

Secondary

Measure	Time frame
Visual acuity,etc.	Exit visit,etc.

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026